Editorial Open Access
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 7, 2011; 17(1): 7-8
Published online Jan 7, 2011. doi: 10.3748/wjg.v17.i1.7
Imaging techniques used for the real-time assessment of angiogenesis in digestive cancers
Adrian Săftoiu, Research Center of Gastroenterology and Hepatology, Gastroenterology Department, University of Medicine and Pharmacy Craiova, Craiova, Dolj, 200349, Romania
Peter Vilmann, Department of Surgical Gastroenterology, Copenhagen University Hospital Herlev, Endoscopic Unit at Gentofte Hospital, 2900 Hellerup, Denmark
Author contributions: Săftoiu A and Vilmann P contributed equally to this paper.
Correspondence to: Adrian Săftoiu, Professor, MD, PhD, MSc, Research Center of Gastroenterology and Hepatology, Gastroenterology Department, University of Medicine and Pharmacy Craiova, 2-4 Petru Rares, Craiova, Dolj, 200349, Romania. adrian.saftoiu@webmail.umfcv.ro
Telephone: +40-744-823355 Fax: +40-251-310287
Received: July 2, 2010
Revised: August 29, 2010
Accepted: October 6, 2010
Published online: January 7, 2011

Abstract

Angiogenesis has a critical role in primary tumor growth and the development of metastases. Several angiogenesis inhibitors were recently developed, being a very attractive target for digestive tumor therapy. However, individualized therapy should not only be based on the pre-treatment imaging evaluation, but also on sensitive monitoring of microvascular changes during treatment. State-of-the-art imaging techniques have the potential to visualize and characterize angiogenesis, although the technology and methodologies employed are recent and need further validation. The aim of this series of reviews was to analyze and enhance current knowledge and future perspectives about the real-time assessment of angiogenesis in digestive cancers, used for the longitudinal monitoring of the effects of chemo-radiotherapy (including anti-angiogenic therapies), as well as for the precise targeting of drugs through molecular-based drug-delivery systems.

Key Words: Angiogenesis, Digestive cancers, Chemo-radiotherapy



FROM THE EDITOR

Angiogenesis plays a critical role in tumor growth and metastasis. Most of the digestive cancers depend strictly on the development of an adequate blood supply in the form of neovascularization, which has a pivotal role in primary tumor growth and the development of metastasis. Thus, new blood vessels formed inside the tumor are usually highly permeable and provide a route for cancer cells to enter blood circulation[1]. Tumor vascularization has been attracting a lot of attention in recent years due to possible implications in semi-quantitative diagnosis, as well as in prognosis stratification and targeted treatment[2]. There are several ways traditionally proposed for investigation of tumor vascularization, but all these methods have several methodological flaws, including artifacts induced by air or fat [contrast-enhanced transabdominal ultrasound (US)], reduced resolution [contrast-enhanced computer tomography (CT)] or invasiveness (angiography or surgery)[3].

Categorizing the patients through mini-invasive procedures, before chemotherapy or surgery, is of crucial importance. This has implications for the appropriate design of clinical trials, but also for the improvement of the decision making process, by selecting the tumors that are most likely to respond to treatment. Recently developed angiogenesis inhibitors represent a highly attractive target for tumor therapy, since they theoretically offer the hope of long-term control of tumor progression[4]. Several anti-angiogenic inhibitors were recently developed and have already been proven to be effective in clinical trials: bevacizumab (recombinant humanized anti-VEGF monoclonal antibody), cetuximab (anti-EGFR monoclonal antibody), erlotinib (tyrosine-kinase inhibitor), etc[5]. Even though anti-angiogenic treatments are an established anti-cancer therapy, several mechanisms of tumor evasion and refractoriness have been described after inhibition of a single pro-angiogenic pathway, due to compensatory upregulation of different angiogenic pathways[6]. Tailoring the anti-angiogenesis therapy as a function of the pre-operative imaging evaluation would be the next step, with a consequent decrease of toxicity, as well as an increase of median progression-free survival. Furthermore, these procedures would possibly allow a sensitive monitoring of microvascular changes caused by chemoradiotherapy or other ablative treatments. The ultimate goal would be to achieve an early diagnosis where the “angiogenic switch” could be delayed and tumor evasion mechanisms could be prevented, in order to induce a dormant state, while transforming cancer into a chronic disease[7].

The main objectives of our series of reviews include the discussion of several advanced imaging techniques, complementary used for the real-time assessment of angiogenesis in digestive cancers. The advanced imaging techniques discussed will include several “red-flag” endoscopic techniques used for the depiction of minute changes in the vessel pattern of preneoplastic and neoplastic lesions (trimodal imaging including autofluorescence imaging, zoom endoscopy and narrow band imaging)[8]. Utility of Doppler-optical coherence tomography (D-OCT) for the depiction and quantification of low-velocity, low-volume blood flow will also be reviewed[9]. These techniques will be supplemented by the presentation of confocal laser endomicroscopy and the potential applications of this breakthrough technique for the in-vivo assessment of vascularization based on the use of specific vascular contrast agents[10]. Targeted contrast-enhanced ultrasound and its role in the depiction of angiogenesis, as well as ultrasound-directed drug delivery and the physics behind sonoporation will also be discussed[11]. A comprehensive discussion will focus also on the use of contrast-enhanced endoscopic ultrasound (including specific harmonic imaging)[12]. Current and future hybrid imaging techniques like real-time virtual sonography (a combination of US/EUS with CT/magnetic resonance imaging) will also be briefly described[13]. Lastly, molecular imaging perspectives and new developments of targeted contrast agents will be critically analyzed[14].

The aim of this series of reviews will be to analyze and enhance the current knowledge and future perspectives of the in-vivo, real-time assessment of angiogenesis in digestive cancers, used for the longitudinal monitoring of the effects of chemo-radiotherapy (including antiangiogenic therapies), as well as for the precise targeting of drugs through molecular based drug-delivery systems.

Footnotes

Peer reviewer: Tsuneo Kitamura, Associate Professor, Department of Gastroenterology, Juntendo University Urayasu Hospital, Juntendo University School of Medicine, 2-1-1 Tomioka, Urayasu-shi, Chiba 279-0021, Japan

S- Editor Sun H L- Editor Rutherford A E- Editor Ma WH

References
1.  Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med. 2003;3:643-651.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Ellis LM, Walker RA, Gasparini G. Is determination of angiogenic activity in human tumours clinically useful? Eur J Cancer. 1998;34:609-618.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Kitano M, Kudo M, Maekawa K, Suetomi Y, Sakamoto H, Fukuta N, Nakaoka R, Kawasaki T. Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut. 2004;53:854-859.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Saif MW. Anti-angiogenesis therapy in pancreatic carcinoma. JOP. 2006;7:163-173.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Liu CC, Shen Z, Kung HF, Lin MC. Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol. 2006;12:6941-6948.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010;13:16-28.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Naumov GN, Folkman J, Straume O, Akslen LA. Tumor-vascular interactions and tumor dormancy. APMIS. 2008;116:569-585.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Filip M, Iordache S, Săftoiu A, Ciurea T. Autofluorescence imaging and magnification endoscopy. World J Gastroenterol. 2011;17:9-14.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Osiac E, Săftoiu A, Gheonea DI, Mandrila I, Angelescu R. Optical coherence tomography and Doppler optical coherence tomography in the gastrointestinal tract. World J Gastroenterol. 2011;17:15-20.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Gheonea DI, Cârţână T, Ciurea T, Popescu C, Bădărău A, Săftoiu A. Confocal laser endomicroscopy and immunoendoscopy for real-time assessment of vascularization in gastrointestinal malignancies. World J Gastroenterol. 2011;17:21-27.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Postema M, Gilja OH. Contrast-enhanced and targeted ultrasound. World J Gastroenterol. 2011;17:28-41.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Reddy NK, Ioncică AM, Săftoiu A, Vilmann P, Bhutani MS. Contrast-enhanced endoscopic ultrasonography. World J Gastroenterol. 2011;17:42-48.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Sandulescu DL, Dumitrescu D, Rogoveanu I, Saftoiu A. Hybrid ultrasound imaging techniques (fusion imaging). World J Gastroenterol. 2011;17:49-52.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Thekkek N, Anandasabapathy S, Richards-Kortum R. Optical molecular imaging for detection of Barrett’s-associated neoplasia. World J Gastroenterol. 2011;17:53-62.  [PubMed]  [DOI]  [Cited in This Article: ]